Nonacog beta pegol

Drug Profile

Nonacog beta pegol

Alternative Names: 40K PEG-rFIX; Glycopegylated rFIX - Novo Nordisk; La-rFIX derivative - Novo Nordisk; N9 GP; NN 7999; NNC-0156-0000-0009; REBINYN; Refixia

Latest Information Update: 08 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Haemophilia B

Most Recent Events

  • 06 Jun 2017 Registered for Haemophilia B (Prevention and treatment, In adolescents, In adults) in European Union, Norway, Iceland, Liechtenstein (IV)
  • 31 May 2017 Registered for Haemophilia B (In infants, In children, In adolescents, In adults) in USA (IV)
  • 31 May 2017 Novo Nordisk expects to launch Nonacog beta pegol (REBINYN®) in the US in 1H 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top